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Abstract
Background: Treat to target (T2T) is widely accepted as the standard of care for patients with rheumatoid arthritis
(RA) and has been shown to be more effective than traditional routine care. The objective of this study was to
compare the effectiveness of two T2T strategies in patients with early RA: a step-up approach starting with
methotrexate (MTX) monotherapy (cohort I) versus an initial disease-modifying antirheumatic drug combination
approach (cohort II).
Methods: A total of 128 patients from cohort II were case–control-matched with 128 patients from cohort I on
gender, age, and baseline disease activity. Twelve-month follow-up data were available for 121 patients in both
cohorts. The primary outcome was the proportion of patients having reached at least one 28-joint Disease Activity
Score (DAS28) score <2.6 (remission) during 12 months of follow-up. Secondary outcomes were time until
remission was achieved and mean DAS28 scores at 6- and 12-month follow-up.
Results: After 12 months of follow-up, remission was reached at least once in 77.3 % of the patients in cohort II
versus 71.9 % in cohort I (P = 0.31). Median time until first remission was 17 weeks in cohort II versus 27 weeks in
cohort I (P = 0.04). A significant time by strategy interaction was found in mean DAS28 scores. Post hoc analysis
revealed a significant difference in mean DAS28 scores between both cohorts at 6 months (P = 0.04), but not at
12 months (P = 0.36).
Conclusions: The initial combination strategy resulted in a comparable remission rate after 1 year but a
significantly shorter time until remission. At 6 months, mean DAS28 scores were lower in patients with initial
combination treatment than in those with step-up therapy. At 12 months, no significant differences remained in
mean DAS28 scores or the proportion of patients in remission.
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Background
Treat to target (T2T) is widely accepted as the standard of
care for patients with rheumatoid arthritis (RA) and is
now recommended in national and international guide-
lines [1, 2]. Under the controlled conditions of random-
ized clinical trials, T2T aimed at remission or low disease
activity leads to good clinical outcomes [3–5]. Further-
more, it has been shown that T2T is more effective than
traditional routine care, especially when a protocol treat-
ment strategy is used [6]. Recently, it was shown that T2T
also leads to more rapid and higher 28-joint Disease
Activity Score (DAS28) remission rates and larger im-
provements in functional ability and patient assessments
than usual care in daily clinical practice [7]. Previous clin-
ical trials have additionally compared the effectiveness of
different disease-modifying antirheumatic drug (DMARD)
strategies, including initial monotherapy, initial combin-
ation therapy, or step-up combination therapy with and
without the use of corticosteroids or biologics [5, 8–13].
On the basis of these trials, initial combination therapy
appears to be more effective than initial monotherapy
[5, 12, 14], while the combination of methotrexate (MTX)
monotherapy with high-dose step-down prednisone seems
to have equally good results [11, 15]. However, the optimal
treatment protocol is still not clear.
A challenge in the field of RA management remains the
implementation of T2T strategies in daily clinical practice.
Healthcare professionals may be reluctant to prescribe
complex combination therapies, including high-dose cor-
ticosteroids, because of concerns about patient compli-
ance and unfavorable side effects [16]. Moreover, time
constraints and problems with organizational structures
and processes can complicate successful implementation
of T2T in daily clinical practice [17]. T2T starting with
MTX monotherapy was successfully implemented in the
first Dutch Rheumatoid Arthritis Monitoring (DREAM)
registry remission induction cohort [18–20]. Despite very
promising results, T2T did not have the same impact on
all patients [21]. A relevant proportion of patients still did
not reach clinical remission within 12 months of treat-
ment [18]. DREAM registry remission induction cohort I
was used in the first observational study to describe the
results of implementing a T2T strategy in daily clinical
practice. Subsequent studies using different T2T strategies
are needed to establish which strategy gives the optimal
result in daily clinical practice.
Consequently, a second inception cohort was started
(cohort II), in which patients were treated with initial
combination DMARD therapy consisting of high-dose
MTX and hydroxychloroquine (HCQ) with an optional
intramuscular triamcinolone acetonide (TCA) injection
at the discretion of the rheumatologist. The aim of the
present study was to compare the clinical outcomes of
both treatment strategies after 1 year of follow-up.
Methods
Data selection and study design
In this study, we used data from the ongoing DREAM
registry remission induction strategies I and II, two obser-
vational, multicenter cohorts established in 2006 and 2012,
respectively. In both cohorts, all adults aged ≥18 years with
a clinical diagnosis of RA and a disease duration (time from
the diagnosis to the start of therapy) <1 year were enrolled
consecutively immediately after a clinical diagnosis of RA.
For this study, data from two hospitals were used: Medisch
Spectrum Twente in Enschede and Isala Klinieken in
Zwolle, both in the Netherlands. Both treatment strategies
were in line with clinical practice and complied with
current guidelines for treatment of RA. Exclusion criteria
for both cohorts were use of prednisolone ≥10 mg/day or
previous or current treatment with DMARDs. The medical
ethics committees of the Medisch Spectrum Twente,
Enschede and Isala, Zwolle hospitals determined, in ac-
cordance with Dutch law, that no ethical approval was re-
quired, because all data were collected in the course of
regular daily clinical practice. Nonetheless, patients were
completely informed about the study, and informed con-
sent was obtained from each patient.
At the time of the present analysis, 137 patients had a
follow-up of at least 1 year in cohort II. For the aim of
this quasi-experimental study, a total of 128 patients
from cohort II could be individually matched with 128
patients from cohort I on sex, age (±5 years) and base-
line disease activity (±0.5 on the DAS28).
Treat-to-target protocol
T2T protocol in cohort I
Patients were evaluated at 0, 8, 12, 20, 24, 36, and 52 weeks
and every 3 months thereafter. Per-protocol treatment ad-
vice was an initial monotherapy of 15 mg/week MTX,
with folic acid taken on the second day after MTX. In case
of insufficient response (DAS28 ≥ 2.6) at the first subse-
quent time point, the following per-protocol treatment
steps were advised. After 2 months, the MTX dosage was
increased to 25 mg/week; after 3 months, sulfasalazine
(SSZ) 2000 mg/day was added. After 20 weeks, the SSZ
dosage was increased to 3000 mg/day. In accordance with
Dutch reimbursement regulations, anti–tumor necrosis
factor (anti-TNF)-α treatment was prescribed at week 24
for patients whose DAS28 remained ≥3.2. In these cases,
SSZ was replaced with subcutaneous administration of
40 mg of adalimumab every 2 weeks. At week 36, the fre-
quency of adalimumab was increased to 40 mg/week for
patients with DAS28 ≥ 2.6. At week 52, adalimumab was
exchanged for etanercept 50 mg/week for patients with
DAS28 ≥ 3.2. If at any time point the target of DAS28 < 2.6
was met, medication was held constant. In case of sus-
tained remission (≥6 months), medication was gradually
reduced and eventually discontinued. In case of a disease
Steunebrink et al. Arthritis Research & Therapy  (2016) 18:60 Page 2 of 9
flare (DAS28 ≥ 2.6), the last effective medication or
medication dose was restarted and treatment could subse-
quently be intensified. In individual patients with contrain-
dications to specific medication, deviations from the
protocol were allowed. In patients with an allergy to sulfa
drugs (sulfonamides), SSZ was replaced by oral HCQ at a
dosage of 400 mg/day. Concomitant treatment with non-
steroidal anti-inflammatory drugs, prednisolone at a dos-
age of ≤10 mg/day, and intraarticular corticosteroid
injections was allowed at the discretion of the attending
rheumatologist. On clinical indication, the attending
rheumatologist was free to diverge from the medication
schedule at any time. Further details of the study protocol
are reported elsewhere [18].
T2T protocol in cohort II
Patients were evaluated at months 0, 2, 4, and 6 and
every 3 months thereafter. Treatment advice was an ini-
tial combination therapy of MTX 20 mg/week and HCQ
200 mg twice daily. As bridging therapy, an optional
intramuscular triamcinolone injection to a maximum
dosage of 120 mg could be given. After 1 month, the
MTX dosage was increased to 25 mg/week, independent
of disease activity. All patients who started MTX also re-
ceived folic acid on the second day after MTX. After
2 months, in case of persistent disease activity (DAS28 ≥
2.6), the MTX dosage was further increased to 30 mg/week
and an extra optional intramuscular triamcinolone injection
could be administered. After 4 months, in case of
moderate to high disease activity (DAS28 ≥ 3.2), a TNF in-
hibitor (adalimumab, etanercept, or infliximab) was added.
In case of low disease activity (2.6 < DAS28 < 3.2), the at-
tending rheumatologist could choose between SSZ 2000–
3000 mg/day or an intramuscular triamcinolone injection.
Similarly to cohort I, disease activity was assessed
using the DAS28 at each subsequent visit. If remission
(DAS28 < 2.6) had not been reached, treatment was in-
tensified. If the patient was in DAS28 remission, medica-
tion was held constant. In case of sustained remission
(≥6 months), medication was tapered and eventually dis-
continued according to a predetermined tapering sched-
ule. In case of disease flare (DAS28 ≥ 2.6), the last
effective medication or medication dosage was restarted
and treatment could subsequently be intensified. On
clinical indication, the attending rheumatologist was free
to diverge from the medication schedule at any time. For
patients with contraindications to specific medications,
deviations from the protocol were also allowed.
Assessments
At each assessment, data were collected on various clinical
and patient-reported outcome measures, including mea-
sures of disease activity, health-related quality of life, phys-
ical function, and laboratory measures. Disease activity
was assessed by trained rheumatology nurses using the
DAS28, consisting of swollen and tender joint counts in
28 joints, the erythrocyte sedimentation rate (ESR), and a
100-mm visual analogue scale (VAS) on general health
(0 = “very good” and 100 = “very bad”) [22]. The Health
Assessment Questionnaire Disability Index (HAQ-DI) was
used to assess physical function [23]. Furthermore, pa-
tients rated their pain on a 100-mm VAS (0 = “no pain”
and 100 = “unbearable pain”) and completed the 36-item
Short Form Health Survey (SF-36) for assessment of their
current physical and mental health status [24].
Outcome measures
The primary outcome was the proportion of patients
having reached at least one DAS28 < 2.6 (DAS28 remis-
sion) after 1 year of follow-up. Secondary outcomes were
time until remission was achieved and changes in mean
DAS28 scores at 6 months and 1 year.
Statistical analysis
All statistical calculations were performed using the stat-
istical software package IBM SPSS version 20.0 for
Windows (IBM, Armonk, NY, USA). Missing values for
ESR (1.8 %) and well-being (0.3 %) were imputed on the
basis of swollen and tender joint counts and C-reactive
protein (CRP) using single imputation with the expect-
ation–maximization method in SPSS. Descriptive statis-
tics for normally distributed variables or categorical
variables were reported as frequencies, means, and
standard deviations. If variables were not normally dis-
tributed, the median with the corresponding interquar-
tile range was reported. To test for any baseline
differences, we performed independent t tests for nor-
mally distributed variables, Mann–Whitney U tests for
nonnormally distributed variables, and χ2 tests for cat-
egorical variables. Differences in the proportion of pa-
tients achieving remission were tested using χ2 tests. To
compare time until first moment of DAS28 remission,
Kaplan-Meier survival analysis was used with log-rank
testing for between-group differences. The course of
DAS28 over time was compared between groups by spe-
cifying a linear mixed model with strategy and time as
fixed factors. As the visit schedules were slightly differ-
ent between both cohorts, only baseline, 6-month, and
12-month data were used for this analysis. An ante-
dependence structure was used as a model for the co-
variance matrix because it gave the best fit to the data.
Post hoc analysis of covariance (ANCOVA) was per-
formed with baseline DAS28 score as a covariate. For all
tests, P < 0.05 was considered to be significant.
Results
Table 1 summarizes baseline patient characteristics of
both cohorts. All patients had active disease with a mean
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DAS28 of 4.8 ± 1.1 in cohort II versus 4.5 ± 1.1 in cohort
I. Twelve-month data were available for 121 patients
(94.5 %) in both cohorts. In cohort I, seven patients were
lost to follow-up, of whom one had received another
diagnosis (systemic lupus erythematosus), four were lost
to follow-up for unknown reasons, and two had no 12-
month visit (but were still in the cohort). In cohort II,
seven patients were lost to follow-up, of whom one died,
one achieved medication-free remission, one was mis-
diagnosed as having arthritis, two were lost to follow-up
for unknown reasons, and two had no 12-month visit
(but were still in the cohort).
Remission
First remission within 6 months was achieved in 63.3 % (81
of 128) of the patients in cohort II versus 48.4 % (62 of 128)
in cohort I (P = 0.02). First remission within 12 months was
achieved in 77.3 % (n = 99 of 128) of the patients in cohort
II versus 71.9 % (92 of 128) in cohort I (P = 0.31). Median
time until first remission was 17 weeks (95 % confidence
interval [CI] 13.2–20.8) in cohort II versus 27 weeks (95 %
CI 20.7–33.3) in cohort I (P = 0.04) (Fig. 1).
The proportion of patients in remission in cohorts II
and I at the time of the 6-month assessments were
61.7 % (74 of 120) and 45.9 % (56 of 122) (P = 0.01), re-
spectively. The proportion of patients in remission in co-
horts II and I at the 12-month assessments were 63.6 %
(77 of 121) and 60.3 % (n = 73 of 121) (P = 0.60). The
majority of the patients in both cohorts reached their
first remission using the initial medication only. In co-
hort II, 84.8 % achieved remission with MTX +HCQ,
while in cohort I 63.0 % achieved remission with MTX
monotherapy.
Course over time of the DAS28
Figure 2 represents the mean DAS28 over time in both
cohorts. A significant time by strategy interaction was
found (P = 0.01), indicating a different pattern of DAS28
change over time between both cohorts. At 6 months,
the mean DAS28 in cohort II was below the cutoff for
remission (DAS28 < 2.6), while the mean DAS28 in co-
hort I was still above remission (DAS28 > 2.6). At
12 months, mean DAS28 was <2.6 in both cohorts. Ac-
cording to the post hoc ANCOVA, mean DAS28 scores
Table 1 Baseline characteristics of patients in both cohorts
Characteristics Cohort I (n = 128) Cohort II (n = 128) P value
Female sex, n (%) 79 (61.7 %) 79 (61.7 %) 1.00
Age, years, mean ± SD 59.1 ± 13.0 59.5 ± 12.8 0.81
DAS28-ESR, mean ± SD 4.5 ± 1.1 4.8 ± 1.1 0.02
ESR, mm/h, median (IQR) 22.0 (14.0–41.0) 29.0a (14.0–45.0) 0.20
CRP, mg/L, median (IQR) 10.0b (5.0–22.0) 11.5 (4.3–24.8) 0.79
Anti-CCP–positive, n (%) 74c (58.3 %) 77c (60.2 %) 0.93
RF-positive, n (%) 62 (48.4 %) 76 (59.4 %) 0.11
SJC, n, median (IQR) 6.0 (3.0–9.0) 5.0 (2.0–10.0) 0.24
TJC, n, median (IQR) 3.0 (1.0–7.0) 4.0 (2.0–10.0) 0.03
HAQ-SDI, median (IQR) 1.19d (0.88–1.63) 1.0e (0.38–1.50) <0.01
VAS well-being, median (IQR) 50.0 (28.3–65.0) 51.0 (35.0–70.0) 0.29
VAS pain, median (IQR) 50.0f (39.8–64.0) 62.0g (49.0–75.0) <0.01
SF-36-PCS, mean ± SD 38.1 ± 7.6h 37.3 ± 9.2i 0.51
SF-36-MCS, mean ± SD 40.7 ± 7.4j 44.9 ± 11.9k 0.00
BMI, kg/m2, mean ± SD 26.5 ± 4.8l 26.0 ± 4.1m 0.39
DAS28-ESR Disease Activity Score in 28 joints using erythrocyte sedimentation rate, CRP C-reactive protein, TJC tender joint count, SJC swollen joint count, HAQ-SDI
Health Assessment Questionnaire Disability Index (standard scoring), SF-36 36-item Short Form Health Survey (version 2), PCS Physical Component Summary, MCS
Mental Component Summary, BMI body mass index, RF rheumatoid factor, CCP cyclic citrullinated peptide, VAS visual analogue scale
an = 127
bn = 121
cn = 127
dn = 102
en = 87
fn = 122
gn = 72
hn = 105
in = 86
jn = 105
kn = 86
ln = 126
mn = 119
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were significantly lower in cohort II at 6 months (mean
difference 0.30, 95 % CI 0.01–0.58, P = 0.04) but not at
12 months (mean difference 0.13, 95 % CI −0.14 to 0.40,
P = 0.36).
Medication use
At baseline, 67 patients (53.3 %) in cohort II received an
intramuscular injection with triamcinolone versus 4
patients (3.1 %) in cohort I (P < 0.01). Receiving an injec-
tion with triamcinolone in cohort II was associated with
a higher odds ratio (OR 2.14, 95 % CI 1.03–4.46, P =
0.04) of achieving first remission within 6 months but
no longer with achieving remission within 12 months
(OR 1.77, 95 % CI 0.77–4.10, P = 0.018). The actual
medication used at 12 months (Table 2) was significantly
different between both cohorts (P = 0.03). The vast
Fig. 1 Kaplan-Meier curves for time until first remission was reached. The solid line represents cohort II, and the dashed line represents cohort I
Fig. 2 Decrease in mean 28-joint Disease Activity Score (DAS28) in treat to target cohort II versus cohort I in 1 year. The dashed line represents
cohort II, and the solid line represents cohort I
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majority of the patients in both cohorts received conven-
tional synthetic disease-modifying antirheumatic drugs
(csDMARDs) only at 12 months. A small percentage of
the patients in both cohorts were prescribed a biologic
DMARD. In cohort II, there were slightly more patients
for whom DMARD therapy was fully discontinued.
Discussion
The results of this study suggest that the previously re-
ported outcomes that were achieved by implementation
of T2T with initial MTX monotherapy in daily clinical
practice may be reproduced, and even improved upon,
using an initial combination approach. In the present
study, DAS28 remission was reached at least once in
77.3 % of the patients in cohort II versus 71.9 % in co-
hort I in 1 year of follow-up. Although after 1 year there
was no significant difference in the number of patients
who had reached remission, remission was reached sig-
nificantly more rapidly, with a median time to first re-
mission of 17 weeks in cohort II versus 27 weeks in
cohort I. A significant difference between strategies in
mean DAS28 scores was also found at 6 months, but no
longer at 12 months. Therefore, T2T using initial com-
bination therapy may not be superior in the number of
patients achieving remission in the longer term, but the
strategy does lead to a significantly shorter time until
first remission is achieved.
Researchers in various T2T studies in patients with
recent-onset RA have reported remission rates varying
from 10 % to 78 % [25]. However, it should be noted
that these remission rates are difficult to compare, as the
investigators in these studies used different criteria for
remission and reported slightly different follow-up pe-
riods. The TICORA study had the highest proportion
(65 %) of patients in remission (defined as DAS44 < 1.6)
after 18 months of follow-up so far [4]. In the BeST
study, the overall proportion of patients in DAS44 re-
mission at 1 year was 32 %, with no differences between
the four therapeutic groups [26]. The CAMERA group
reported that 35 % of the patients in the intensive group
attained remission (defined as no swollen joints and at
least two of three of the following criteria: number of
tender joints ≤3, ESR ≤20 mm/h, and VAS general well-
being ≤20 mm) for a period of 3 months after 1 year of
follow-up [3]. The IMPROVED study showed an early
DAS44 remission rate of 61 % [15]. The CareRA trial re-
searchers, comparing three different intensive combin-
ation strategies with glucocorticoids, reported DAS28
(based on CRP) remission rates ranging from 68.1 % to
73.6 % within 16 weeks [27]. The tREACH trial investi-
gators compared two triple-DMARD induction therapies
with MTX monotherapy and reported that approxi-
mately 78 % of the patients using triple-DMARD therapy
had a DAS <2.4 after 3 months, compared with 60 % of
the patients using MTX monotherapy [28].
The present study shows that both DREAM registry
remission induction cohorts I and II resulted in compar-
ably high proportions of patients achieving remission
within 12 months. While the implementation of a proto-
col T2T may in itself explain the high remission rates in
both cohorts, apparently even better results may be
attained regarding the time needed to achieve first re-
mission by implementing initial combination protocols
in daily clinical practice. This is in accordance with pre-
vious randomized clinical trials. Among the different
therapeutic strategies, early combination therapy that in-
cluded high-dose step-down DMARDs and low-dose ste-
roids was shown to be most effective in the management
of early RA [8, 26, 29–31]. Low-dose prednisone added
to conventional DMARD treatment in patients with
early RA induced earlier and better disease activity con-
trol and provided greater probability for a more stable
clinical remission over time [32]. A strict protocol, fre-
quent monitoring, and the commitment and adherence
of doctors and nurses may also contribute to optimal
outcomes in daily clinical practice [6, 33].
Differences in disease activity and in time until remis-
sion are clinically important and are likely to also have
significant social and economic impact. For instance, pa-
tients with persistently active disease are more likely to
discontinue work [34]. The DREAM registry remission
induction cohort I already showed the feasibility of sus-
tained remission in daily clinical practice [16]. Cohort II
also demonstrated impressive improvements in disease
activity, comparable with or even better than that re-
ported in previous studies of combination therapy for
RA [5, 8, 11–13, 18]. In the present study, mean DAS28
scores were significantly lower in cohort II than in co-
hort I at 6 months but not at 12 months. This is in line
with clinical trials showing that initial combination ther-
apy appears to result in more rapid improvements in
disease activity, daily functioning, and quality of life than
initial monotherapy [4, 11, 26, 35].
Optimal use of MTX in combination with other
DMARDs early in the course of the disease leads to con-
siderable improvement in disease activity [3, 4, 19]. Un-
fortunately, previous studies show some conflicting
results regarding the efficacy of monotherapy versus
Table 2 Medication at 12 months
Medication Cohort I (n = 128) Cohort II (n = 128)
No DMARD 2 (1.6 %) 10 (7.8 %)
csDMARD only 116 (90.6 %) 104 (81.3 %)
bDMARD 5 (3.9 %) 11 (8.6 %)
Lost to follow-up 5 (3.9 %) 3 (2.3 %)
DMARD disease-modifying antirheumatic drug, csDMARD conventional synthetic
disease-modifying antirheumatic drug, bDMARD biologic disease-modifying
antirheumatic drug
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combination therapy. Double- or triple-combination
therapy appears to lead to better clinical outcomes than
MTX monotherapy [13, 26, 35]. The TEAR trial con-
cluded that combination treatment was more effective
than MTX monotherapy before step-up therapy [14].
The CARDERA study, which was not an initial combin-
ation therapy, showed that intensive combination ther-
apy with MTX, ciclosporin, and glucocorticosteroids
after failure of MTX monotherapy leads to sustained
benefits in damage and disability outcomes [36]. How-
ever, a recent study done in Belgium (the CareRA trial)
showed that in high-risk patients with RA, MTX in
combination with a moderate step-down dose of gluco-
corticosteroids was as effective in inducing remission as
DMARD combination therapies with moderate or high
step-down glucocorticosteroid doses [27]. In contrast,
the tREACH trial showed that a DMARD combination
was better than MTX monotherapy, both in combin-
ation with low-dose glucocorticoid bridging [12]. In the
United States, MTX +HCQ is by far the DMARD com-
bination most commonly prescribed by rheumatologists
[37]. It has been shown to be more potent than MTX
used alone [38]. An explanation for this may be that
HCQ increases the bioavailability of MTX and/or re-
duces the clearance of the drug [39].
In the present study, the vast majority of the patients
in both cohorts achieved the treatment target using
csDMARDs only, and a small number of the patients in
both cohorts were using biologic DMARDs at 12 months.
This highlights again the importance of the initial treat-
ment choice for the majority of the patients.
It should be noted that the present study was a quasi-
experimental study of two cohorts separated over time.
The first cohort started in 2006 with MTX monother-
apy, and the second cohort started in 2012 with a
DMARD combination therapy. Although we did not
conduct a randomized trial, we still think that the design
and results of the study allow us to compare the two co-
horts. The cohorts consist of very similar populations of
all consecutive newly diagnosed patients with RA treated
in the same hospitals by the same rheumatologists. Pa-
tients in cohort II were additionally case–control-
matched with patients in cohort I on gender, age, and
baseline disease activity. Although baseline disease activ-
ity, disability, and pain were slightly but significantly
worse in cohort II, the number of patients achieving re-
mission within 6 months was even higher in this cohort.
Moreover, post hoc analyses of mean DAS28 scores con-
trolling for baseline disease activity produced very simi-
lar results.
Because in our study we used real-life observational
data, the results are generalizable to daily clinical prac-
tice. Longer follow-up is needed to investigate the sus-
tainability of remission in cohort II. However, previous
studies have shown that a shorter time until remission is
related to the sustainability of remission, supporting the
importance of early intervention with effective therapy
to achieve early remission [40]. Although the remission
rates in this study were very high, there is still a small
percentage of patients who do not achieve remission,
thus creating a need to further identify predictors of re-
mission [21].
Conclusions
Initial RA combination therapy with high-dose MTX,
HCQ, and optional intramuscular TCA was not superior
in achieving the number of patients in remission after
1 year, but it did result in a shorter time until first remis-
sion versus a step-up approach using MTX and SSZ in
the setting of T2T therapy in daily clinical practice.
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